Sumary of Polymeric and lipid nanoparticles in self-amplifying RNA vaccines result in higher protein expression and immunogenicity:
- Thanks to its self-amplification properties, much lower doses (typically 100-fold lower) of saRNA are sufficient for vaccine production compared to messenger RNA (mRNA).
- saRNA, being a versatile platform, can be used to generate vaccines against any pathogen with a known protein target, including influenza, chlamydia, HIV-1, Ebola, and RSV.
- First-in-human clinical trial against SARS-CoV-2 to test the potency and scalability of the saRNA technology The potential of saRNA was recently tested for the first time in humans in a combined Phase I/II clinical trial against SARS-CoV-2. The study demonstrated the potency and scalability of the saRNA technology.
- ” The researchers first compared the in vivo protein expression of saRNA formulated with pABOL and several LNP formulations.
- They then compared the matching formulations with saRNA encoding the influenza hemagglutinin (HA) glycoprotein as a model antigen to assess differences in immunogenicity.
- They also investigated the dose-response curve for LNP against the SARS-CoV-2 spike glycoprotein protein antigen and compared intramuscular (IM) and intranasal (IN) routes of administration.
- pABOL-formulated saRNA resulted in higher protein expression, while LNP formulations improved immunogenicity The researchers observed that pABOL-formulated saRNA led to higher protein expression, but the LNP formulations were more immunogenic.
- IN administration of LNP affected vaccine immunogenicity of 2 model antigens – HA and SARS-CoV-2 spike protein.